Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel
Study Details
Study Description
Brief Summary
The safety and efficacy of once daily application of IDP 126 Gel will be compared to Epiduo® Forte and IDP-126 Vehicle Gel.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Detailed Description
This is a multicenter, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, tolerability, and efficacy of IDP-126 Gel in comparison with Epiduo® Forte gel and IDP-126 Vehicle Gel at Weeks 2, 4, 8, and 12. To be eligible for the study, subjects must be at least 12 years of age and have a clinical diagnosis of moderate to severe acne (defined as an Evaluator's Global Severity Score [EGSS] of 3 or 4), presenting with 30-100 inflammatory facial lesions (papules, pustules, and nodules), 35-150 non-inflammatory facial lesions (open and closed comedones), and ≤ 2 facial nodules.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: IDP-126 Gel
|
Drug: IDP-126 Gel
Gel applied to face once daily in the evening.
Other Names:
|
Placebo Comparator: IDP-126 Vehicle Gel
|
Drug: IDP-126 Vehicle Gel
Gel applied to face once daily in the evening.
Other Names:
|
Active Comparator: Epiduo® Forte Gel
|
Drug: Epiduo® Forte Gel
Gel applied to face once daily in the evening.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Absolute change from Baseline to Week 12 in lesion counts. [Baseline to Week 12]
- Percentage of subjects who achieve at least a two-grade reduction from baseline and are "Clear" or "Almost Clear" at Week 12 in the Evaluator's Global Severity Score. [Baseline to Week 12]
EGSS evaluations will be scored on a scale of 0-4, with 0 being clear and 4 being severe.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male or female at least 12 years of age and older.
-
Written and verbal informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit).
-
Subject must have an EGSS of 3 (moderate) or 4 (severe) at the baseline visit.
-
Subjects with a facial acne inflammatory lesion (papules, pustules, and nodules) count no less than 30, but no more than 100.
-
Subjects with a facial acne non-inflammatory lesion (open and closed comedones) count no less than 35, but no more than 150.
-
Subjects with 2 or fewer facial nodules.
Exclusion Criteria:
-
Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram negative folliculitis, dermatitis, eczema.
-
Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive.
-
Subjects with more than 2 facial nodules.
-
Female subjects who are pregnant, nursing mothers, planning a pregnancy during the course of the study, or become pregnant during the study.
-
Use of estrogens (eg, Depogen, Depo-Testadiol, Gynogen, Valergen, etc) for less than 12 weeks immediately preceding study entry; subjects treated with estrogens 12 or more consecutive weeks immediately prior to study entry need not be excluded unless the subject expects to change dose, drug or discontinue estrogen use during the study.
-
Treatment of any type of cancer within the last 6 months, with the exception of complete surgical excision of skin cancer outside the treatment area.
-
Subjects who have not undergone specified washout period(s) for topical preparations/physical treatments used on the face or subjects who require the concurrent use in the treatment area.
-
Subjects who have not undergone specified washout period(s) for systemic medications or subjects who require the concurrent use of systemic medications.
-
Subjects with any underlying disease that the investigator deems uncontrolled, and poses a concern for the subject's safety while participating in the study.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Bausch Site 134 | Bryant | Arkansas | United States | 72022 |
2 | Bausch Site 118 | Rogers | Arkansas | United States | 72758 |
3 | Bausch Site 110 | Fremont | California | United States | 94538 |
4 | Bausch Site 101 | Manhattan Beach | California | United States | 90266 |
5 | Bausch Site 106 | San Diego | California | United States | 92123 |
6 | Bausch Site 112 | San Diego | California | United States | 92123 |
7 | Bausch Site 128 | San Diego | California | United States | 92123 |
8 | Bausch Site 105 | Boynton Beach | Florida | United States | 33437 |
9 | Bausch Site 126 | Clearwater | Florida | United States | 33761 |
10 | Bausch Site 135 | North Miami Beach | Florida | United States | 33162 |
11 | Bausch Site 143 | Sanford | Florida | United States | 32771 |
12 | Bausch Site 102 | Tampa | Florida | United States | 33607 |
13 | Bausch Site 104 | West Palm Beach | Florida | United States | 33401 |
14 | Bausch Site 122 | West Palm Beach | Florida | United States | 33406 |
15 | Bausch Site 124 | Newnan | Georgia | United States | 30263 |
16 | Bausch Site 127 | Boise | Idaho | United States | 83704 |
17 | Bausch Site 129 | Louisville | Kentucky | United States | 40241 |
18 | Bausch Site 139 | Mandeville | Louisiana | United States | 70448 |
19 | Bausch Site 121 | Metairie | Louisiana | United States | 70006 |
20 | Bausch Site 116 | Rockville | Maryland | United States | 20850 |
21 | Bausch Site 103 | Brighton | Massachusetts | United States | 21350 |
22 | Bausch Site 120 | New Brighton | Minnesota | United States | 55112 |
23 | Bausch Site 108 | Las Vegas | Nevada | United States | 89148 |
24 | Bausch Site 119 | New York | New York | United States | 10022 |
25 | Bausch Site 133 | New York | New York | United States | 10075 |
26 | Bausch Site 142 | High Point | North Carolina | United States | 27262 |
27 | Bausch Site 109 | Dublin | Ohio | United States | 43016 |
28 | Bausch Site 117 | Oklahoma City | Oklahoma | United States | 73112 |
29 | Bausch Site 107 | Gresham | Oregon | United States | 97030 |
30 | Bausch Site 114 | Nashville | Tennessee | United States | 37215 |
31 | Bausch Site 111 | Austin | Texas | United States | 78759 |
32 | Bausch Site 132 | Houston | Texas | United States | 77098 |
33 | Bausch Site 123 | Pflugerville | Texas | United States | 78660 |
34 | Bausch Site 137 | Spokane | Washington | United States | 99202 |
35 | Bausch Site 136 | Kortrijk | Belgium | ||
36 | Bausch Site 140 | Maldegem | Belgium | ||
37 | Bausch Site 138 | Winnipeg | Manitoba | Canada | R3M 3Z4 |
38 | Bausch Site 125 | Markham | Ontario | Canada | L3P 1X3 |
39 | Bausch Site 141 | Oakville | Ontario | Canada | L6J 7W5 |
40 | Bausch Site 115 | Peterborough | Ontario | Canada | K91 5K2 |
41 | Bausch Site 130 | Waterloo | Ontario | Canada | N2J 1C4 |
42 | Bausch Site 113 | Saint-Jérôme | Quebec | Canada | J7Z 7E2 |
Sponsors and Collaborators
- Bausch Health Americas, Inc.
Investigators
- Study Director: Varsha Bhatt, Bausch Health Americas, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- V01-126A-202